Summit Therapeutics PLC (ADR) (SMMT) Reaches $13.62 After 8.00% Up Move; Ensemble Capital Management Has Upped Its Now (DNOW) Position

July 26, 2017 - By Marguerite Chambers

Ensemble Capital Management Llc increased Now Inc (DNOW) stake by 10.69% reported in 2016Q4 SEC filing. Ensemble Capital Management Llc acquired 79,315 shares as Now Inc (DNOW)’s stock declined 12.97%. The Ensemble Capital Management Llc holds 821,040 shares with $16.81 million value, up from 741,725 last quarter. Now Inc now has $1.80B valuation. The stock declined 0.18% or $0.03 reaching $16.27 on the news. About 570,133 shares traded. NOW Inc (NYSE:DNOW) has risen 9.86% since July 26, 2016 and is uptrending. It has underperformed by 6.84% the S&P500.

The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) is a huge mover today! About 50,312 shares traded or 447.23% up from the average. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 33.22% since July 26, 2016 and is uptrending. It has outperformed by 16.52% the S&P500.The move comes after 9 months positive chart setup for the $160.96 million company. It was reported on Jul, 26 by Barchart.com. We have $14.71 PT which if reached, will make NASDAQ:SMMT worth $12.88 million more.

Analysts await Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) to report earnings on September, 14. They expect $1.38 EPS, up 312.31% or $2.03 from last year’s $-0.65 per share. SMMT’s profit will be $16.31 million for 2.47 P/E if the $1.38 EPS becomes a reality. After $-0.50 actual EPS reported by Summit Therapeutics PLC (ADR) for the previous quarter, Wall Street now forecasts -376.00% EPS growth.

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The company has market cap of $160.96 million. The Firm is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It currently has negative earnings. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).

Among 6 analysts covering Summit Therapeutic (NASDAQ:SMMT), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Summit Therapeutic has $29 highest and $2400 lowest target. $26.75’s average target is 96.40% above currents $13.62 stock price. Summit Therapeutic had 8 analyst reports since August 19, 2015 according to SRatingsIntel. Janney Capital initiated the stock with “Buy” rating in Tuesday, June 21 report. H.C. Wainwright initiated the shares of SMMT in report on Friday, September 16 with “Buy” rating. H.C. Wainwright maintained Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) on Thursday, July 6 with “Buy” rating. Oppenheimer maintained Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) on Thursday, June 22 with “Buy” rating. The firm earned “Buy” rating on Thursday, June 15 by Canaccord Genuity. The stock has “Hold” rating by Zacks on Tuesday, September 1. The firm has “Buy” rating given on Wednesday, August 19 by Oppenheimer. The rating was maintained by RBC Capital Markets on Wednesday, November 16 with “Outperform”.

Investors sentiment increased to 0.96 in Q4 2016. Its up 0.01, from 0.95 in 2016Q3. It improved, as 32 investors sold DNOW shares while 88 reduced holdings. 38 funds opened positions while 77 raised stakes. 107.32 million shares or 1.48% less from 108.93 million shares in 2016Q3 were reported. Ngam Advsrs Limited Partnership has 0.03% invested in NOW Inc (NYSE:DNOW). New York State Teachers Retirement System holds 0.01% in NOW Inc (NYSE:DNOW) or 183,762 shares. M&R Cap Mngmt Incorporated has 8,628 shares. 3,025 are held by Brown Brothers Harriman &. Rbo And Limited Liability has invested 2.36% in NOW Inc (NYSE:DNOW). Quantbot Technology Limited Partnership invested 0.01% of its portfolio in NOW Inc (NYSE:DNOW). Raymond James Trust Na invested in 10,618 shares or 0.02% of the stock. 22,675 were reported by Highbridge Cap Management Limited Co. 168,453 were reported by D E Shaw. Dekabank Deutsche Girozentrale holds 0% or 6,300 shares in its portfolio. Cacti Asset Mngmt Lc, Georgia-based fund reported 2,500 shares. Utd Ser Automobile Association has 0% invested in NOW Inc (NYSE:DNOW) for 64,577 shares. Group One Trading LP accumulated 1,846 shares or 0% of the stock. United Kingdom-based Blackrock Group Inc Limited has invested 0% in NOW Inc (NYSE:DNOW). Pnc Svcs Group Inc owns 14,689 shares.

Among 11 analysts covering Now Inc (NYSE:DNOW), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Now Inc had 20 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of NOW Inc (NYSE:DNOW) earned “Buy” rating by Seaport Global on Thursday, May 4. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, July 6. Stephens upgraded the shares of DNOW in report on Friday, May 5 to “Overweight” rating. The stock of NOW Inc (NYSE:DNOW) has “Market Perform” rating given on Friday, September 16 by Cowen & Co. The stock of NOW Inc (NYSE:DNOW) earned “Overweight” rating by KeyCorp on Monday, May 29. The rating was downgraded by Stephens on Thursday, August 6 to “Equal Weight”. The stock of NOW Inc (NYSE:DNOW) earned “Outperform” rating by Robert W. Baird on Wednesday, April 26. The rating was upgraded by Susquehanna on Tuesday, January 10 to “Positive”. The stock has “Neutral” rating by Credit Suisse on Tuesday, September 15. JP Morgan maintained NOW Inc (NYSE:DNOW) rating on Wednesday, February 24. JP Morgan has “Neutral” rating and $12 target.